Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zovegalisib + atirmociclib + fulvestrant
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Zovegalisib + atirmociclib + fulvestrant is an investigational triplet combination regimen being evaluated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer harboring PIK3CA (PI3Kα) mutations. The regimen consists of three active agents: zovegalisib (RLY-2608), a mutant-selective, allosteric PI3Kα inhibitor developed by Relay Therapeutics; atirmociclib (PF-07220060), a selective CDK4 inhibitor developed by Pfizer; and fulvestrant, a standard-of-care selective estrogen receptor degrader (SERD). By selectively targeting mutant PI3Kα and CDK4 while sparing wild-type PI3Kα and CDK6, the combination aims to maximize antitumor efficacy and overcome endocrine resistance while minimizing toxicities such as hyperglycemia and neutropenia. In the Phase 1/2 ReDiscover trial, the triplet demonstrated encouraging clinical activity and a manageable safety profile in heavily pretreated patients.
- Other names
- RLY-2608 + PF-07220060 + fulvestrantzovegalisib + atirmociclib + fulvestrant regimenzovegalisib, atirmociclib, and fulvestrantzovegalisib/atirmociclib/fulvestrant
02
Targets
CDK4 (Cyclin-dependent kinase 4)ESR1 (ERα)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on zovegalisib + atirmociclib + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zovegalisib + atirmociclib + fulvestrant.